I2D I2D PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (0950-9232) 2011 imex curation Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net 23-Sept-2011: Contacted by JYOTI. mgt Only protein-protein interactions Curated by: I2D - Interologous Interaction Database human-mda_mb_468 Homo sapiens MDA-MB-468 mda_mb_468 MDA-MB-468 breast adenocarcinoma Species: human, Black; Tissue: breast; Tumor: adenocarcinoma; Derived from: pleural effusion anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net Accepted 2011-SEP-12 by MGT 23-Sept-2011: Contacted by JYOTI. Oncogene (0950-9232) 2011 mgt Only protein-protein interactions imex curation Curated by: I2D - Interologous Interaction Database PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (0950-9232) 2011 imex curation Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net 23-Sept-2011: Contacted by JYOTI. mgt Only protein-protein interactions Curated by: I2D - Interologous Interaction Database human-mcf7 Homo sapiens mammary carcinoma cells mcf7 mammary carcinoma cells bifunctional agent crosslink protein cross-linking with a bifunctional reagent Label transfer techniques Photoaffinity labelling Label transfer techniques Photoaffinity labelling bifunctional agent crosslink western blot western blot Immuno blot Immuno blot Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net Accepted 2011-SEP-12 by MGT 23-Sept-2011: Contacted by JYOTI. Oncogene (0950-9232) 2011 mgt Only protein-protein interactions imex curation Curated by: I2D - Interologous Interaction Database PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (0950-9232) 2011 imex curation Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net 23-Sept-2011: Contacted by JYOTI. mgt Only protein-protein interactions Curated by: I2D - Interologous Interaction Database human-bt474 Homo sapiens breast ductal carcinoma cell line bt474 Human breast ductal carcinoma cell line BT474 Human breast ductal carcinoma cell line established from a solid, invasive ductal carcinoma of the breast obtained from a 60-year-old woman. bifunctional agent crosslink protein cross-linking with a bifunctional reagent Label transfer techniques Photoaffinity labelling Label transfer techniques Photoaffinity labelling bifunctional agent crosslink western blot western blot Immuno blot Immuno blot Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net Accepted 2011-SEP-12 by MGT 23-Sept-2011: Contacted by JYOTI. Oncogene (0950-9232) 2011 mgt Only protein-protein interactions imex curation Curated by: I2D - Interologous Interaction Database PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (0950-9232) 2011 imex curation Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net 23-Sept-2011: Contacted by JYOTI. mgt Only protein-protein interactions Curated by: I2D - Interologous Interaction Database human-mcf7 Homo sapiens mammary carcinoma cells mcf7 mammary carcinoma cells anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Serra V., Scaltriti M., Prudkin L., Eichhorn PJ., Ibrahim YH., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., Gili M., Russillo M., Parra JL., Singh S., Arribas J., Rosen N., Baselga J. Cancer - Interactions investigated in the context of cancer After membrane cross-linking, lysates were subjected to anti-HER2 co-IP. jbaselga@vhio.net Accepted 2011-SEP-12 by MGT 23-Sept-2011: Contacted by JYOTI. Oncogene (0950-9232) 2011 mgt Only protein-protein interactions imex curation Curated by: I2D - Interologous Interaction Database erbb3_human Receptor tyrosine-protein kinase erbB-3 Tyrosine kinase-type cell surface receptor HER3 ERBB3 HER3 Proto-oncogene-like protein c-ErbB-3 protein protein human Homo sapiens Human MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT DIP protein P21860 original sequence version: 175 DIP protein P21860 original sequence version: 125 DIP protein P21860 original sequence version: 172 DIP protein P21860 original sequence version: 130 DIP protein P21860 original sequence version: 157 DIP protein P21860 original sequence version: 137 7201E7F66CA374BD grb2_human Growth factor receptor-bound protein 2 GRB2 ASH Adapter protein GRB2 SH2/SH3 adapter GRB2 Protein Ash protein protein human Homo sapiens Human MEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRGDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV 83A4B0BA1B248DC4 p85a_human Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 GRB1 Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha protein protein human Homo sapiens Human MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR DIP protein P27986 original sequence version: 181 DIP protein P27986 original sequence version: 184 DIP protein P27986-1 original sequence version: 135 DIP protein P27986 original sequence version: 135 DIP protein P27986-1 original sequence version: 145 DIP protein P27986-1 original sequence version: 147 DIP protein P27986 original sequence version: 191 B9DAD8416C33140F egfr_human Epidermal growth factor receptor ERBB1 EGFR Receptor tyrosine-protein kinase erbB-1 Proto-oncogene c-ErbB-1 ERBB HER1 protein protein human Homo sapiens Human MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA DIP protein P00533 original sequence version: 213 DIP protein P00533 original sequence version: 214 DIP protein P00533 original sequence version: 119 DIP protein P00533 original sequence version: 207 DIP protein P00533 original sequence version: 132 DIP protein P00533-1 original sequence version: 197 DIP protein P00533 original sequence version: 163 DIP protein P00533-1 original sequence version: 159 DIP protein P00533 original sequence version: 184 DIP protein P00533-1 original sequence version: 174 DIP protein P00533-1 original sequence version: 191 DIP protein P00533 original sequence version: 218 DIP protein P00533 original sequence version: 221 DIP protein P00533-1 original sequence version: 221 DIP protein P00533 original sequence version: 226 DIP protein P00533 original sequence version: 166 DIP protein P00533-1 original sequence version: 166 DIP protein P00533 original sequence version: 194 DIP protein P00533-1 original sequence version: 194 DIP protein P00533-1 original sequence version: 224 DIP protein P00533 original sequence version: 189 DIP protein P00533-1 original sequence version: 207 DIP protein P00533 original sequence version: 177 DIP protein P00533 original sequence version: 168 D8A2A50B4EFB6ED2 erbb2_human Receptor tyrosine-protein kinase erbB-2 p185erbB2 MLN19 Proto-oncogene c-ErbB-2 Tyrosine kinase-type cell surface receptor HER2 Proto-oncogene Neu ERBB2 HER2 NEU NGL Metastatic lymph node gene 19 protein protein protein human Homo sapiens Human MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV DIP protein P04626 original sequence version: 198 DIP protein P04626 original sequence version: 122 DIP protein P04626 original sequence version: 206 DIP protein P04626 original sequence version: 195 DIP protein P04626 original sequence version: 150 DIP protein P04626 original sequence version: 179 DIP protein P04626 original sequence version: 146 DIP protein P04626 original sequence version: 147 39E9DFDA04DCF962 erbb2-erbb3-3 3 5 unspecified role unspecified role prey prey 9 unspecified role unspecified role bait bait physical association physical association 3a Binding increases in the presence of p110/mTor inhibitor BEZ235. erbb2-erbb3-4 2 9 unspecified role unspecified role bait bait 5 unspecified role unspecified role prey prey physical association physical association 3a Binding increases in the presence of p110/mTor inhibitor BEZ235. erbb2-grb2 4 6 unspecified role unspecified role prey prey 9 unspecified role unspecified role bait bait physical association physical association 3b There is a dose-dependent increase in binding between HER2 and GRB2 in cells treated with BEZ235. egfr-erbb2 2 9 unspecified role unspecified role prey prey 8 unspecified role unspecified role bait bait physical association physical association S5A Membrane EGFR dimerization to HER2 or HER3 was not detected following treatment with BEZ235 egfr-erbb3 2 5 unspecified role unspecified role prey prey 8 unspecified role unspecified role bait bait physical association physical association S5a Membrane EGFR dimerization to HER2 or HER3 could not be detected following treatment with BEZ235 egfr-grb2-2 4 6 unspecified role unspecified role prey prey 8 unspecified role unspecified role bait bait physical association physical association S5B egfr-grb2-3 1 6 unspecified role unspecified role prey prey 8 unspecified role unspecified role bait bait physical association physical association S5B egfr-egfr-4 2 8 putative self putative self putative self putative self physical association physical association S5a pik3r1-erbb3-1 4 7 unspecified role unspecified role bait bait 5 unspecified role unspecified role prey prey physical association physical association 3b, S5b The association of p85 and HER3 increases after treatment with increasing amounts of BEZ235 for 24hrs. pik3r1-erbb3 1 7 unspecified role unspecified role bait bait 5 unspecified role unspecified role prey prey physical association physical association S5b